Derek Archila
Stock Analyst at Wells Fargo
(3.62)
# 868
Out of 4,761 analysts
166
Total ratings
45.95%
Success rate
7.76%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Downgrades: Equal-Weight | $43 → $14 | $5.80 | +141.38% | 2 | Feb 18, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $40 → $51 | $18.59 | +174.34% | 3 | Feb 13, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $8 → $6 | $2.32 | +158.62% | 4 | Jan 30, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $639 → $723 | $644.48 | +12.18% | 10 | Dec 19, 2024 | |
| ZYME Zymeworks | Maintains: Equal-Weight | $12 → $14 | $14.39 | -2.71% | 5 | Dec 19, 2024 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $11 → $9 | $6.05 | +48.76% | 11 | Dec 19, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $68 → $70 | $72.11 | -2.93% | 6 | Dec 19, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $47 → $45 | $21.27 | +111.57% | 9 | Dec 19, 2024 | |
| CABA Cabaletta Bio | Downgrades: Equal-Weight | $12 → $6 | $2.06 | +191.26% | 8 | Dec 19, 2024 | |
| CCCC C4 Therapeutics | Upgrades: Overweight | $8 → $12 | $3.01 | +298.67% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $14 → $11 | $6.22 | +76.85% | 4 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $16.27 | +65.95% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $2.60 | +400.00% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $95 → $16 | $2.57 | +522.57% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $36.81 | +54.85% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $2.78 | +763.31% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $30 | $27.52 | +9.01% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $92.25 | +63.69% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $36 | $36.85 | -2.31% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.32 | +293.52% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $152.43 | +89.60% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.61 | +583.23% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $22.46 | +64.74% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.81 | +255.87% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $60 | $17.77 | +237.65% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $56.07 | -7.26% | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $16.87 | +18.55% | 4 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.82 | +998.90% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.84 | +533.80% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.83 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $26.74 | +621.77% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $98.10 | -58.21% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $8 | $0.59 | +1,258.00% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $4.40 | +1,265.19% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.43 | +554.63% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.73 | +2,790.17% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $10.08 | +405.95% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $25.34 | +247.28% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $25.16 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.74 | - | 2 | Aug 3, 2017 |
Septerna
Feb 18, 2025
Downgrades: Equal-Weight
Price Target: $43 → $14
Current: $5.80
Upside: +141.38%
AnaptysBio
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $18.59
Upside: +174.34%
Zentalis Pharmaceuticals
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $2.32
Upside: +158.62%
argenx SE
Dec 19, 2024
Maintains: Overweight
Price Target: $639 → $723
Current: $644.48
Upside: +12.18%
Zymeworks
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $14.39
Upside: -2.71%
Kezar Life Sciences
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $6.05
Upside: +48.76%
Incyte
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $68 → $70
Current: $72.11
Upside: -2.93%
Immunovant
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $21.27
Upside: +111.57%
Cabaletta Bio
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $12 → $6
Current: $2.06
Upside: +191.26%
C4 Therapeutics
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $3.01
Upside: +298.67%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $14 → $11
Current: $6.22
Upside: +76.85%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $16.27
Upside: +65.95%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $2.60
Upside: +400.00%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $95 → $16
Current: $2.57
Upside: +522.57%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $36.81
Upside: +54.85%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $2.78
Upside: +763.31%
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $27.52
Upside: +9.01%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $92.25
Upside: +63.69%
Oct 30, 2024
Maintains: Overweight
Price Target: $32 → $36
Current: $36.85
Upside: -2.31%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $4.32
Upside: +293.52%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $152.43
Upside: +89.60%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.61
Upside: +583.23%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $22.46
Upside: +64.74%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.81
Upside: +255.87%
May 9, 2024
Maintains: Overweight
Price Target: $63 → $60
Current: $17.77
Upside: +237.65%
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $56.07
Upside: -7.26%
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $16.87
Upside: +18.55%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.82
Upside: +998.90%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $2.84
Upside: +533.80%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.83
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $26.74
Upside: +621.77%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $98.10
Upside: -58.21%
Mar 31, 2020
Maintains: Hold
Price Target: $24 → $8
Current: $0.59
Upside: +1,258.00%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $4.40
Upside: +1,265.19%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.43
Upside: +554.63%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.73
Upside: +2,790.17%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $10.08
Upside: +405.95%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $25.34
Upside: +247.28%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $25.16
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.74
Upside: -